3McNeela EA, Jabbal-Gill I, Illum L, et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine, 2004, 22:909-914.
4Nagamoto T, Hattori Y, Takayama K, et al. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res, 2004, 21: 671-674.
5Vila A, Sanchez A, Janes K, et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm, 2004, 57: 123-131.
6Lubben IM, Verhoef JC, Borchard G, et al. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci,2001, 14: 201-207.
7Shibata Y, Foster LA, Metzger WJ, et al. Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-D-glucosamine, in mice. Infect Immun, 1997, 65:1734-1741.
8Westerink MA, Smithson SL, Srivastava N, et al. ProJuvant(Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine, 2001, 20:711-723.
9Sakagami T, Dixon M, O'Rourke J, et al. Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut, 1996, 39:639-648.
10Mills KH, Cosgrove C, McNeela EA, et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun, 2003,71:726-732.
